We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Croda International Plc | LSE:CRDA | London | Ordinary Share | GB00BJFFLV09 | ORD 10.609756P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
36.00 | 0.78% | 4,655.00 | 4,653.00 | 4,656.00 | 4,673.00 | 4,576.00 | 4,622.00 | 33,039 | 09:43:43 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 1.69B | 171M | 1.2246 | 37.94 | 6.49B |
Date | Subject | Author | Discuss |
---|---|---|---|
22/11/2021 11:13 | @rafboy Since August 2020 Croda has completed four acquisitions: Avanti Polar Lipids - US lipids Iberchem - Fragrants Alban Muller - Natural Ingredients Parfex - Fragrants (purchase by Iberchem) May 2021 it announced a "strategic review" of its Industrial Chemicals business. A lot to speculate about for future performance and returns is my guess. | sogoesit | |
19/11/2021 14:00 | Moving up but on what I wonder! | rafboy | |
12/11/2021 19:08 | Croda are key to Nanoparticle supply for future rna vaccines not just Covid. OK it is only one of the products, but having just hit a 3 bagger for me today , I remain optimistic about the future here. | wad collector | |
23/9/2021 11:30 | Beginning to think this, at 45x, may have more to go... 50x forward P/E for the current year? Any takers? Edit 28/09: Or not! Inflation, rising interest rates now kicking-in... Edit 26/10: or possibly yes... ;-)) Anyway, accumulated during the seasonal slump. | sogoesit | |
05/8/2021 11:50 | Closing-in on my 45x forward earnings price target... Will it, won't it? EDIT: Yep, 45 x 1.1 x 2 = 90 (give or take a fiver). GLA | sogoesit | |
05/8/2021 09:51 | Croda International PLC - Yorkshire, England-based chemicals maker - Non-Executive Director Keith Layden and Julie Layden sell 19,975 shares in total at GBP86.10, worth GBP1.7 million, on Wednesday,4th Aug. | steeplejack | |
30/7/2021 15:28 | Indeed, let’s hope it grows back into its historic 45x p/e for us holders left behind… | sogoesit | |
28/7/2021 08:36 | smart move uncle sam as profit takers move in ! | arja | |
27/7/2021 13:01 | yes , but prospective p/e figure will still be quite high and CRDA would be hit if anything went a bit wrong . But share price keeps shooting up and how long is a piece of string ! | arja | |
27/7/2021 12:57 | “….. profit…. significantly ahead of current expectations.” Those woz the key words! | sogoesit | |
27/7/2021 12:36 | but a real NOR situation and not sure it is smart to exit unless you trade the stock of course . Maybe sell half under BHR policy but you follow the stock more than I do and US indices may tank at any time . | arja | |
27/7/2021 08:55 | Excellent results. Astounding share price. But while their business model is positive global macro predictions are less so. Am taking profits here. | uncle_sam | |
27/7/2021 07:48 | From today’s HY Results: “Outlook The first half year has seen a strong performance across the Group, reflecting the global recovery in demand, the accelerated implementation of our strategic priorities and increased investment. We expect underlying growth across all sectors to continue in the second half year, driven by consumer demand, whilst the customer restocking seen in the first half is expected to moderate. Together with the benefit of recent acquisitions opening up new fast growth markets, we expect continued strong demand for lipid systems and are increasing guidance for sales this year to at least US$200m. We now expect 2021 full year adjusted profit before tax to be significantly ahead of current expectations. Subject to there being no material change in current market conditions, we expect a similar phasing of profit between the first and second half periods as seen in previous years. Demand for COVID-19 solution ingredients remains uncertain beyond the short term and the current level of sales could moderate; however, we expect to see an ongoing expansion in the range of applications for lipid systems in vaccines and therapeutic drugs over the medium term. Across the wider Group, the combination of our differentiated business model, healthy innovation pipeline and recent investment is expected to underpin performance and continue to generate increased value for all our stakeholders.” | sogoesit | |
14/12/2020 01:54 | Just to mention that the Xmas MelloMonday special guest may mention Croda and I think shareholders and potential investors will appreciate his thoughts. There is an interview tonight with Keith Ashworth Lord who is a highly respected fund manager and well worth listening to. Keith's fund Castlefield are of course one of the larger shareholders in Croda and I think it is one of their top ten positions. The Mello Monday event starts at 6pm The full programme is available on the website. Also of interest may be the MelloBASH... The analysts, fund manager and well known investors on the panel will give their honest verdicts on whether four companies are a Buy Avoid Sell or Hold at this current juncture in the markets. All investors welcome and if you use the code MMTADVFN50 you will get a half price ticket. Great investor content and entertainment. We had nearly 400 investors attend last month so these are very popular. | davidosh | |
13/11/2020 08:08 | Market does not appear to like the Sky News story - its still going down. Anyone know why? I would have thought winning the covid19 contract from Phizer has to be good news as one would expect the other vaccines will also have to buy from Croda (they probably are all very similar). | netcurtains | |
12/11/2020 18:00 | Yep that’s what the runs said on the 10th with the £100 mil deal, surprised by the lack of interest | nerja | |
12/11/2020 16:04 | Sky news??? Croda working with Phizer, that is good news!!! | lysandrospanayi | |
10/11/2020 13:51 | Get in there! | nerja | |
16/9/2020 17:05 | ‘Vaccine adjuvant hopes perhaps?’ Could be. Looking really expensive now! | frazboy | |
27/7/2020 17:27 | Vaccine adjuvant hopes perhaps? | dab26 | |
27/7/2020 17:24 | I'm not sure tbh.....would love to be able to call the top of this one as think it has a long way to fall, even considering their latest investment. Is it a solid company?....yes. Do current results justify a breakout...not imo. I'm not sure their outlook is too rosy either as not all their segments are doing well in a Covid world. | lyndon b | |
27/7/2020 15:51 | Could also be a short squeeze? There was approaching 5% stock on loan prior to results. I wouldn't have thought the results were good enough to make the shorters run for the hills but they were perhaps better than expected. Marshall Wace has, for example, been short from much lower down. | frazboy | |
27/7/2020 14:50 | I think the only explanation is the dividend (and it being maintained, while most other companies have not held it in place). Big investors are holding for that reason and getting a capital gain to boot.If you look at the financials of this company on their own (profit down 10%), some margin erosion in their high end personal care segment, some business segment links to automotive/oil industry etc etc, then the share price gain/ALL TIME HIGH makes zero sense.Based on current/future trading against historical, then £50/share makes better sense, though as we all know SP's rarely make sense. | lyndon b | |
27/7/2020 13:34 | it's a good question arja... it's clearly a benefactor of having some growth (in particular, in the life science area), and being resolute. Perhaps the greatest driver of the price of late is long term bond yields falling - discounting of future earnings at a lower rate helps drive valuations. can't see it rising much further, and, in fact, I'm looking for a short opportunity, but i'm not fighting the current trend. | frazboy | |
27/7/2020 10:22 | what is so special about this stock as , even on a bearish day, it keeps hitting new al time highs . ? tempting to buy but maybe too risky after such a run ! | arja |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions